bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from MELK Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Meel Michaël H. , de Gooijer Mark C. , Guillén Navarro Miriam , Waranecki Piotr , Breur Marjolein , Buil Levi C.M. , Wedekind Laurine E. , Twisk Jos W.R. , Koster Jan , Hashizume Rintaro , Raabe Eric H. , Montero Carcaboso Angel , Bugiani Marianna , van Tellingen Olaf , van Vuurden Dannis G. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

Ingenuity pathway analysis (IPA) of upstream factors capable of regulating differentially expressed genes in HSJD-DIPG-12, HSJD-DIPG-07, SF7761 and JHH-DIPG-01 cells treated for 24 hours with 20 nM OTSSP167.
Supplementary Table S6 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Table S6. Univariate and multivariate Cox proportional hazard regression models of the 27-gene signature using the Kim (A), Lindgren (B), Sjodahl (C), and TCGA (D) data sets. Univariate Cox proportional hazard regression analysis showed that a gene signature of top 50% was significantly associated with increased risk of death in Kim, Lindgren, and Sjodahl cohorts (hazard ratio (HR) above 1). In a multivariate model, after adjusted for other factors such as sex, age and tumor stage showed that the 27 gene signature of top 50% was associated with increased risk of death in TCGA, Kim, and Lindgren. Tumor stage was significantly associated with survival in all TCGA, Kim, Sjodahl and Lindgren cohorts, and age was significantly associated with survival in TCGA and Kim cohorts. Hazard ratios (HRs) derived from Cox proportional hazards models are expressed with 95% confidence intervals (CIs) and p-values. For all analyses, p-value <0.05 was considered clinically significant and was highlighted in green.
Figure S1 from Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Authors: Gallois Claire , Taieb Julien , Le Corre Delphine , Le Malicot Karine , Tabernero Josep , Mulot Claire , Seitz Jean-François , Aparicio Thomas , Folprecht Gunnar , Lepage Côme , Mini Enrico , Van Laethem Jean-Luc , Emile Jean-François , Laurent-Puig Pierre
Published: April 2023

Figure S1 shows analysis steps for determine the CIMP status
Table S1 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Table S1. Treatment for patients with gastric cancer in the training, internal and external validation cohorts.
Supplemental legend and tables from Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling
Authors: Griewank Klaus G. , Koelsche Christian , van de Nes Johannes A.P. , Schrimpf Daniel , Gessi Marco , Möller Inga , Sucker Antje , Scolyer Richard A. , Buckland Michael E. , Murali Rajmohan , Pietsch Torsten , von Deimling Andreas , Schadendorf Dirk
Published: April 2023

SUPPLEMENTAL FIGURE LEGENDS Supplemental Table 1. Genes covered in the 29 gene sequencing panel Supplemental Table 2. Genes covered in the 10 gene uveal melanoma panel Supplemental Table 3. Distribution of tumors with available follow-up data Supplemental Table 4. Comparison of 47 tumors categorized using the Brat et al. classification (grey) and the genetic risk-based classification outlined in the present study (black)
Supplementary Data from SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Authors: Kinneer Krista , Meekin John , Tiberghien Arnaud C. , Tai Yu-Tzu , Phipps Sandrina , Kiefer Christine Mione , Rebelatto Marlon C. , Dimasi Nazzareno , Moriarty Alyssa , Papadopoulos Kyriakos P. , Sridhar Sriram , Gregson Stephen J. , Wick Michael J. , Masterson Luke , Anderson Kenneth C. , Herbst Ronald , Howard Philip W. , Tice David A.
Published: April 2023

Supplementary methods and materials, and Supplemental Figures
Table S2 from Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Authors: Atkins Michael B. , Hodi F. Stephen , Thompson John A. , McDermott David F. , Hwu Wen-Jen , Lawrence Donald P. , Dawson Nancy A. , Wong Deborah J. , Bhatia Shailender , James Marihella , Jain Lokesh , Robey Seth , Shu Xinxin , Homet Moreno Blanca , Perini Rodolfo F. , Choueiri Toni K. , Ribas Antoni
Published: April 2023

Dose-Finding Rules for the Pembrolizumab Plus Pegylated Interferon-α2b Cohort
Table S2 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Authors: Odegaard Justin I. , Vincent John J. , Mortimer Stefanie , Vowles James V. , Ulrich Bryan C. , Banks Kimberly C. , Fairclough Stephen R. , Zill Oliver A. , Sikora Marcin , Mokhtari Reza , Abdueva Diana , Nagy Rebecca J. , Lee Christine E. , Kiedrowski Lesli A. , Paweletz Cloud P. , Eltoukhy Helmy , Lanman Richard B. , Chudova Darya I. , Talasaz AmirAli
Published: April 2023

Detailed results of Digital Sequencing and clinical ddPCR comparison. Results shown in individual 2x2 tables for each biomarker tested. *Note, all discordances were below DFCI ddPCR's reportable range. Detailed clinical information for each is presented in Supplemental Table 3.
Supplementary Tables from CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC
Authors: Liu Youyi , Liu Lijuan , Zhou Yan , Zhou Ping , Yan Qiujin , Chen Xiaobei , Ding Shuang , Zhu Fan
Published: April 2023

Supplementary Tables
Supplementary Figure 4 from CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC
Authors: Liu Youyi , Liu Lijuan , Zhou Yan , Zhou Ping , Yan Qiujin , Chen Xiaobei , Ding Shuang , Zhu Fan
Published: April 2023

Knockdown of CKLF1 in HCCLM3 cells result in significantly smaller tumor volume compared to the positive control.
Supplementary Figure 2 from CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC
Authors: Liu Youyi , Liu Lijuan , Zhou Yan , Zhou Ping , Yan Qiujin , Chen Xiaobei , Ding Shuang , Zhu Fan
Published: April 2023

CKLF1 promotes the malignant transformation in HepG2 and Bel7402 cells.
Figure S4 from Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer
Authors: Xu MengMeng , Casio Michael , Range Danielle E. , Sosa Julie A. , Counter Christopher M.
Published: April 2023

Optical density quantification of P-Erk1/2 staining in TBP mice with and without TM treatment.
Table S3 from Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas
Authors: Zhu Haibo , Guo Jing , Shen Yutao , Dong Wei , Gao Hua , Miao Yazhou , Li Chuzhong , Zhang Yazhuo
Published: April 2023

The sequences of shRNAs, miRNA inhibitors and negative control
Table S2 from Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas
Authors: Zhu Haibo , Guo Jing , Shen Yutao , Dong Wei , Gao Hua , Miao Yazhou , Li Chuzhong , Zhang Yazhuo
Published: April 2023

PCR primers of mRNAs and lncRNAs used for qRT-PCR
Figure S1 from Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer
Authors: Xu MengMeng , Casio Michael , Range Danielle E. , Sosa Julie A. , Counter Christopher M.
Published: April 2023

TM reduces anchorage-independent growth of K1 cells.
Supplementary Data from Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma
Authors: Duan Meng , Goswami Shyamal , Shi Jie-Yi , Wu Lin-Jie , Wang Xiao-Ying , Ma Jia-Qiang , Zhang Zhao , Shi Yang , Ma Li-Jie , Zhang Shu , Xi Rui-Bin , Cao Ya , Zhou Jian , Fan Jia , Zhang Xiao-Ming , Gao Qiang
Published: April 2023

Supplementary Methods
Supplementary Data from Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma
Authors: Duan Meng , Goswami Shyamal , Shi Jie-Yi , Wu Lin-Jie , Wang Xiao-Ying , Ma Jia-Qiang , Zhang Zhao , Shi Yang , Ma Li-Jie , Zhang Shu , Xi Rui-Bin , Cao Ya , Zhou Jian , Fan Jia , Zhang Xiao-Ming , Gao Qiang
Published: April 2023

Supplementary Table S4
Supplementary Data from Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma
Authors: Duan Meng , Goswami Shyamal , Shi Jie-Yi , Wu Lin-Jie , Wang Xiao-Ying , Ma Jia-Qiang , Zhang Zhao , Shi Yang , Ma Li-Jie , Zhang Shu , Xi Rui-Bin , Cao Ya , Zhou Jian , Fan Jia , Zhang Xiao-Ming , Gao Qiang
Published: April 2023

Supplementary Table S5
Supplementary Data 3 from Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases
Authors: Chen Fengju , Zhang Yiqun , Gibbons Don L. , Deneen Benjamin , Kwiatkowski David J. , Ittmann Michael , Creighton Chad J.
Published: April 2023

By patient, data for key somatic mutation, copy alteration, and DNA methylation features examined in this study. Provided as an Excel file.
Supplementary Tables 1-4. Supplementary Figure 1 from Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
Authors: Hong David S. , Moore Kathleen , Patel Manish , Grant Stefan C. , Burris Howard A. , William William N. , Jones Suzanne , Meric-Bernstam Funda , Infante Jeffrey , Golden Lisa , Zhang Wei , Martinez Ricardo , Wijayawardana Sameera , Beckmann Richard , Lin Aimee Bence , Eng Cathy , Bendell Johanna
Published: April 2023

Supplementary Table S1. JTJA Study Dose Expansion Cohorts; Supplementary Table S2. Baseline Disease Classifications of SCCHN Patients Supplementary Table S3. Treatment-Emergent Adverse Events Related to Study Treatment in >10% of Patients with Any Tumor Type; Supplementary Table S4. Genetic Alterations in Tumors Corresponding to SCC of the Anus (n=14) and SCCHN (n=34); Supplementary Figure S1. Progression-free Survival by HPV Status in Patients with SCCHN.
Table S13 from The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Authors: Zill Oliver A. , Banks Kimberly C. , Fairclough Stephen R. , Mortimer Stefanie A. , Vowles James V. , Mokhtari Reza , Gandara David R. , Mack Philip C. , Odegaard Justin I. , Nagy Rebecca J. , Baca Arthur M. , Eltoukhy Helmy , Chudova Darya I. , Lanman Richard B. , Talasaz AmirAli
Published: April 2023

cfDNA variants associated with resistance to on-label targeted therapies across six cancer types
Supplemental Materials from A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Authors: Mossé Yael P. , Fox Elizabeth , Teachey David T. , Reid Joel M. , Safgren Stephanie L. , Carol Hernan , Lock Richard B. , Houghton Peter J. , Smith Malcolm A. , Hall David , Barkauskas Donald A. , Krailo Mark , Voss Stephan D. , Berg Stacey L. , Blaney Susan M. , Weigel Brenda J.
Published: April 2023

Figure S1. Percentage of huCD45+ cells in blood (cardiac bleed) of engrafted mice at treatment initiation, then on Days 7, 21 and 42 for control (light grey), mice treated with Schedule A (7 days, BID, dark grey) or Schedule B (5 days BID X 3, black). The hatched bar corresponds to day 0. Medians and ranges are depicted. Figure S2. Percentage of huCD45+ cells in spleens of engrafted mice at treatment initiation, then on Days 7, 21 and 42 for control (light grey), mice treated with Schedule A (7 days, BID, dark grey) or Schedule B (5 days BID X 3, black). The hatched bar corresponds to day 0. Medians and ranges are depicted. Figure S3. Percentage of huCD45+ cells in bone marrows of engrafted mice at treatment initiation, then on Days 7, 21 and 42 for control (light grey), mice treated with Schedule A (7 days, BID, dark grey) or Schedule B (5 days BID X 3, black). The hatched bar corresponds to day 0. Medians and ranges are depicted. Table S1. Alisertib Pharmacokinetic Parameters Table S2. Summary table of in vivo drug responses
Supplemental Table 3 from Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival
Authors: Subbiah Vivek , Lamhamedi-Cherradi Salah-Eddine , Cuglievan Branko , Menegaz Brian A. , Camacho Pamela , Huh Winston , Ramamoorthy Vandhana , Anderson Pete M. , Pollock Raphael E. , Lev Dina C. , Qiao Wei , McAleer Mary Frances , Benjamin Robert S. , Patel Shreyaskumar , Herzog Cynthia E. , Daw Najat C. , Feig Barry W. , Lazar Alexander J. , Hayes-Jordan Andrea , Ludwig Joseph A.
Published: April 2023

Univariate parameters & statistics in those with metastatic disease at diagnosis
Supplementary Table 1 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Authors: Gordevičius Juozas , Kriščiūnas Algimantas , Groot Daniel E. , Yip Steven M. , Susic Miki , Kwan Andrew , Kustra Rafal , Joshua Anthony M. , Chi Kim N. , Petronis Art , Oh Gabriel
Published: April 2023

Summary of samples retained and used for analysis after quality control: individual distribution across treatment visits, treatment follow-up visit times, and measured PSA levels.
Supplementary Figure S4 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Authors: Chen Justin , Haanpää Maria K. , Gruber Joshua J. , Jäger Natalie , Ford James M. , Snyder Michael P.
Published: April 2023

Figure S4. Individual CpG methylation ratios at genes with promoters identified to have statistically significant differences in methylation. Low coverage at the ends of target enrichment regions lead to noise that artificially affects average methylation at ABRAXAS1 (A), MSH2 (B), STK11 (C), and TP53 (D). The gene structures are displayed below the heatmaps at their appropriate locations. Thin grey rectangles indicate the UTRs and thick blue rectangles indicate CDS; introns are represented by dashed lines. Arrows indicate putative TSS starts and the direction of transcription.
Figure S3 from Effect of Perioperative Opioids on Cancer-Relevant Circulating Parameters: Mu Opioid Receptor and Toll-Like Receptor 4 Activation Potential, and Proteolytic Profile
Authors: Xie Nan , Matigian Nicholas , Vithanage Tharindu , Gregory Kye , Nassar Zeyad D. , Cabot Peter J. , Shaw Paul N. , Kirkpatrick Carl M.J. , Cao Kim-Anh Lê , Sturgess David , Parat Marie-Odile
Published: April 2023

Comparison of proteolytic profile between healthy subjects and preoperative patient samples. MMP activity in samples was analysed using gelatine zymography (A) and TIMP activity was analysed using reverse zymography (B). Gels were scanned for densitometric quantitation. Data are shown as mean {plus minus} SEM, n=60 patients and 10 healthy participants, *, p<0.05, **p < 0.01, unpaired Student's t-test (Two-tailed).
Figure S2 from Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Authors: Soumerai Tara E. , Donoghue Mark T.A. , Bandlamudi Chaitanya , Srinivasan Preethi , Chang Matthew T. , Zamarin Dmitriy , Cadoo Karen A. , Grisham Rachel N. , O'Cearbhaill Roisin E. , Tew William P. , Konner Jason A. , Hensley Martee L. , Makker Vicky , Sabbatini Paul , Spriggs David R. , Troso-Sandoval Tiffany A. , Charen Alexandra Snyder , Friedman Claire , Gorsky Mila , Schweber Sarah J. , Middha Sumit , Murali Rajmohan , Chiang Sarah , Park Kay J. , Soslow Robert A. , Ladanyi Marc , Li Bob T. , Mueller Jennifer , Weigelt Britta , Zehir Ahmet , Berger Michael F. , Abu-Rustum Nadeem R. , Aghajanian Carol , DeLair Deborah F. , Solit David B. , Taylor Barry S. , Hyman David M.
Published: April 2023

Comparison of most recurrently mutated genes in MSKCC vs. TCGA cohort
Figure S4 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration
Authors: Liu Qiuli , Tong Dali , Liu Gaolei , Gao Jie , Wang Lin-ang , Xu Jing , Yang Xingxia , Xie Qiubo , Huang Yiqiang , Pang Jian , Wang Luofu , He Yong , Zhang Dianzheng , Ma Qiang , Lan Weihua , Jiang Jun
Published: April 2023

Supplementary Figure S4. The negative control staining and the expression as well as location of CD68+, CD163+ and CD204+ cells in positive control tissue (human lymphoma). (A) The corresponding serial slices of Figure 2E-G were stained without primary antibodies (Magnifications: 10Ã-). (B and C) Slices from human lymphoma tissues were stained for CD68, CD163 and CD204 by IHC staining in serial sections (B), or by immunofluorescence triple and respective double staining (C). (Magnifications: 10Ã- for the left panels, 40Ã- for the right panels in A and B)
Supplementary S2 from Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma
Authors: Cai Zhixiong , Chen Geng , Zeng Yongyi , Dong Xiuqing , Li Zhenli , Huang Yanbing , Xin Fuli , Qiu Liman , Xu Haipo , Zhang Wei , Su Xiaoping , Liu Xiaolong , Liu Jingfeng
Published: April 2023

Figure S2. The concordance of somatic SNVs detected in preoperative plasma sample and matched tumor in enrolled patients. A. The bar plot demonstrating the R2 of Pearson correlation between the SNVs' mutant allele frequency in preoperative plasma and in corresponding tumor tissues. B. The representative scatter plots showing the correlation of somatic SNVs' mutant allele frequency in preoperative plasma between whole exome sequencing and target sequencing. Each somatic SNV is represented as a single circle.
Supplementary Figure S2 from SS18-SSX–Dependent YAP/TAZ Signaling in Synovial Sarcoma
Authors: Isfort Ilka , Cyra Magdalene , Elges Sandra , Kailayangiri Sareetha , Altvater Bianca , Rossig Claudia , Steinestel Konrad , Grünewald Inga , Huss Sebastian , Eßeling Eva , Mikesch Jan-Henrik , Hafner Susanne , Simmet Thomas , Wozniak Agnieszka , Schöffski Patrick , Larsson Olle , Wardelmann Eva , Trautmann Marcel , Hartmann Wolfgang
Published: April 2023

(A) Stable SS18-SSX-expressing SCP-1 cells showed an upregulation of IGF2 promoter P2-4 transcripts (regarding Figure 3A; 28S rRNA used as loading reference). (B) 'N' nuclear and 'C' cytoplasmic protein fractions of SYO-1, FUJI and CME-1 SySa cells demonstrated cytoplasmic localization of phosphorylated YAP (Ser127) and TAZ (Ser89) (Histone H3 and GAPDH used as loading references for the nuclear and cytoplasmic fractions, respectively). (C) In SYO-1 cells, phosphorylation levels of IGF-IR (Tyr1135/6) and AKT (Ser473) were dose-dependently reduced by treatment with increasing concentrations of BMS-754807 (β-Actin used as loading reference). (D) Immunofluorescence staining of SYO-1 cells showed diminished nuclear localization of YAP and TAZ upon BMS-754807 treatment (original magnification x40).
Supplementary Figure S1 from SS18-SSX–Dependent YAP/TAZ Signaling in Synovial Sarcoma
Authors: Isfort Ilka , Cyra Magdalene , Elges Sandra , Kailayangiri Sareetha , Altvater Bianca , Rossig Claudia , Steinestel Konrad , Grünewald Inga , Huss Sebastian , Eßeling Eva , Mikesch Jan-Henrik , Hafner Susanne , Simmet Thomas , Wozniak Agnieszka , Schöffski Patrick , Larsson Olle , Wardelmann Eva , Trautmann Marcel , Hartmann Wolfgang
Published: April 2023

(A) Overall immunoreactivity of SySa tissue specimens (n=65) . TMA tissue cores with at least moderate staining intensity (semi quantitative score {greater than or equal to} 2) and {greater than or equal to} 30% (YAP, TAZ and FOXM1) or {greater than or equal to} 5% (PLK1) positive cells were considered positive. (B) Immunofluorescence staining of SySa cell lines. Nuclear YAP (left panel), DAPI-stained nuclei (middle panel) and merged fluorescence images (right panel) are shown (original magnification x40).
Supplementary Data Table 4 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Authors: Wang Victoria E. , Xue Jenny Y. , Frederick Dennie T. , Cao Yi , Lin Eva , Wilson Catherine , Urisman Anatoly , Carbone David P. , Flaherty Keith T. , Bernards Rene , Lito Piro , Settleman Jeff , McCormick Frank
Published: April 2023

Table S4 shows the moleculared used in the pharmacological screen and the corresponding IC50 values
Supplementary Figure 3 and 4 from Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer–A Perspective on Future Trial Designs
Authors: Ventz Steffen , Trippa Lorenzo , Schoenfeld Jonathan D.
Published: April 2023

Figure S3: Operating characteristics, efficacy scenario 3 (an average of 3.2, 2.4 and 1.6 AEs per patients under toxicity scenarios 1, 2, 3) for RTOG 1016. Figure S4: Operating characteristics, efficacy scenario 1 (an average of 4.8, 3.6 and 2.4 AEs per patients under toxicity scenarios 1, 2, 3) for DeEscalate.
Supplementary Figures from Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma
Authors: Yamamura Kensuke , Izumi Daisuke , Kandimalla Raju , Sonohara Fuminori , Baba Yoshifumi , Yoshida Naoya , Kodera Yasuhiro , Baba Hideo , Goel Ajay
Published: April 2023

Supplementary figures
Supplementary Table 3 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Authors: Blagden Sarah P. , Hamilton Anne L. , Mileshkin Linda , Wong Shirley , Michael Agnieszka , Hall Marcia , Goh Jeffrey C. , Lisyanskaya Alla S. , DeSilvio Michelle , Frangou Eleni , Stronach Euan A. , Gopalakrishna Prashanth , Meniawy Tarek M. , Gabra Hani
Published: April 2023

Adverse events
Supplemental Table 1 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Authors: Chumsri Saranya , Serie Daniel J. , Li Zhuo , Pogue-Geile Katherine L. , Soyano-Muller Aixa E. , Mashadi-Hossein Afshin , Warren Sarah , Lou Yanyan , Colon-Otero Gerardo , Knutson Keith L. , Perez Edith A. , Moreno-Aspitia Alvaro , Thompson E. Aubrey
Published: April 2023

Supplemental Table 1
Table S5 from Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
Authors: Kraya Adam A. , Maxwell Kara N. , Wubbenhorst Bradley , Wenz Brandon M. , Pluta John , Rech Andrew J. , Dorfman Liza M. , Lunceford Nicole , Barrett Amanda , Mitra Nandita , Morrissette Jennifer J.D. , Feldman Michael , Nayak Anupma , Domchek Susan M. , Vonderheide Robert H. , Nathanson Katherine L.
Published: April 2023

Differentially regulated canonical pathways by HRD level in BRCA1/2 Mutated Breast Cancers
Supplementary Data from Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Authors: Wu Rui-Yan , Kong Peng-Fei , Xia Liang-Ping , Huang Yun , Li Zhi-Ling , Tang Yun-Yun , Chen Yu-Hong , Li Xuan , Senthilkumar Ravichandran , Zhang Hai-Liang , Sun Ting , Xu Xue-Lian , Yu Yan , Mai Jia , Peng Xiao-Dan , Yang Dong , Zhou Li-Huan , Feng Gong-Kan , Deng Rong , Zhu Xiao-Feng
Published: April 2023

Supplementary Figures + Supplementary Datas
Supplementary Data from Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Authors: Greally Megan , Chou Joanne F. , Chatila Walid K. , Margolis Matthew , Capanu Marinela , Hechtman Jaclyn F. , Tuvy Yaelle , Kundra Ritika , Daian Foysal , Ladanyi Marc , Kelsen David P. , Ilson David H. , Berger Michael F. , Tang Laura H. , Solit David B. , Diaz Luis A. , Schultz Nikolaus , Janjigian Yelena Y. , Ku Geoffrey Y.
Published: April 2023

PFS analysis by gene alteration occurring in 10% or more of patients who received monotherapy
Labels of supplementary figures from Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer
Authors: Corredor Germán , Wang Xiangxue , Zhou Yu , Lu Cheng , Fu Pingfu , Syrigos Konstantinos , Rimm David L. , Yang Michael , Romero Eduardo , Schalper Kurt A. , Velcheti Vamsidhar , Madabhushi Anant
Published: April 2023

Labels of supplementary figures
Supplementary Data from Whole–Genome Sequencing of Childhood Cancer Survivors Treated with Cranial Radiation Therapy Identifies 5p15.33 Locus for Stroke: A Report from the St. Jude Lifetime Cohort Study
Authors: Sapkota Yadav , Cheung Yin Ting , Moon Wonjong , Shelton Kyla , Wilson Carmen L. , Wang Zhaoming , Mulrooney Daniel A. , Zhang Jinghui , Armstrong Gregory T. , Hudson Melissa M. , Robison Leslie L. , Krull Kevin R. , Yasui Yutaka
Published: April 2023

Supplementary Data with changes
Table S1 from Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization
Authors: Schirripa Marta , Biason Paola , Lonardi Sara , Pella Nicoletta , Pino Maria Simona , Urbano Federica , Antoniotti Carlotta , Cremolini Chiara , Corallo Salvatore , Pietrantonio Filippo , Gelsomino Fabio , Cascinu Stefano , Orlandi Armando , Munari Giada , Malapelle Umberto , Saggio Serena , Fontanini Gabriella , Rugge Massimo , Mescoli Claudia , Lazzi Stefano , Reggiani Bonetti Luca , Lanza Giovanni , Dei Tos Angelo Paolo , De Maglio Giovanna , Martini Maurizio , Bergamo Francesca , Zagonel Vittorina , Loupakis Fotios , Fassan Matteo
Published: April 2023

Supplementary Table
Figure S2 from Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization
Authors: Schirripa Marta , Biason Paola , Lonardi Sara , Pella Nicoletta , Pino Maria Simona , Urbano Federica , Antoniotti Carlotta , Cremolini Chiara , Corallo Salvatore , Pietrantonio Filippo , Gelsomino Fabio , Cascinu Stefano , Orlandi Armando , Munari Giada , Malapelle Umberto , Saggio Serena , Fontanini Gabriella , Rugge Massimo , Mescoli Claudia , Lazzi Stefano , Reggiani Bonetti Luca , Lanza Giovanni , Dei Tos Angelo Paolo , De Maglio Giovanna , Martini Maurizio , Bergamo Francesca , Zagonel Vittorina , Loupakis Fotios , Fassan Matteo
Published: April 2023

Supplementary Figure S2
Supplementary Legend from Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort
Authors: Dihge Looket , Vallon-Christersson Johan , Hegardt Cecilia , Saal Lao H. , Häkkinen Jari , Larsson Christer , Ehinger Anna , Loman Niklas , Malmberg Martin , Bendahl Pär-Ola , Borg Åke , Staaf Johan , Rydén Lisa
Published: April 2023

Supplementary Legend
Figure S4 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Figure S4
Figure S10 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Figure S10
Supplementary Table S1A and S1B from Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma
Authors: Namikawa Kenjiro , Aung Phyu P. , Milton Denái R. , Tetzlaff Michael T. , Torres-Cabala Carlos A. , Curry Jonathan L. , Nagarajan Priyadharsini , Ivan Doina , Ross Merrick , Gershenwald Jeffrey E. , Prieto Victor G.
Published: April 2023

Table S1A. Relationship between RFS and MSS, and size of tumor deposit in the SLN using the cut-off values of < 0.1 mm, 0.1-1.0 mm, and > 1.0 mm (univariate analysis); Table S1B. Relationship between SLN and non-SLN tumor burden using the cut-off values of < 0.1 mm, 0.1-1.0 mm, and > 1.0 mm (univariate analysis)
Supplementary Data from YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer
Authors: Yun Jiyeon , Hong Min Hee , Kim Seok-Young , Park Chae-Won , Kim Soyoung , Yun Mi Ran , Kang Han Na , Pyo Kyoung-Ho , Lee Sung Sook , Koh Jong Sung , Song Ho-Juhn , Kim Dong Kyun , Lee Young-Sung , Oh Se-Woong , Choi Soongyu , Kim Hye Ryun , Cho Byoung Chul
Published: April 2023

Supplementary Figure S1,S2,and S3
Supplementary Figures from Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas
Authors: Zhao Shuang G. , Chen William S. , Das Rajdeep , Chang S. Laura , Tomlins Scott A. , Chou Jonathan , Quigley David A. , Dang Ha X. , Barnard Travis J. , Mahal Brandon A. , Gibb Ewan A. , Liu Yang , Davicioni Elai , Duska Linda R. , Posadas Edwin M. , Jolly Shruti , Spratt Daniel E. , Nguyen Paul L. , Maher Christopher A. , Small Eric J. , Feng Felix Y.
Published: April 2023

Supplementary Figures 1-8 with legends
Supplementary Table S1 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S1
Suppl. Fig. 3 from Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment
Authors: Luo Ren , Firat Elke , Gaedicke Simone , Guffart Elena , Watanabe Tsubasa , Niedermann Gabriele
Published: April 2023

CD8 depletion efficacy in peripheral blood.
Supplementary Tables from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Tables
Supplementary Figure 8 from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Figure 8
Supplementary Figure 7 from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Figure 7
Figure S3 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Authors: Baird Richard D. , van Rossum Annelot G.J. , Oliveira Mafalda , Beelen Karin , Gao Meiling , Schrier Mariette , Mandjes Ingrid A.M. , Garcia-Corbacho Javier , Vallier Anne-Laure , Dougall Greig , van Werkhoven Erik , Linossi Constanza , Kumar Sanjeev , van Tinteren Harm , Callari Maurizio , Beddowes Emma , Perez-Garcia José-Manuel , Rosing Hilde , Platte Else , Nederlof Petra , Schot Margaret , de Vries Schultink Aurelia , Bernards René , Saura Cristina , Gallagher William , Cortès Javier , Caldas Carlos , Linn Sabine C.
Published: April 2023

Time to progression per patient in a swimmers plot (all patients, N=30)
Supplementary Figure 3D from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Exploratory Analysis of Different MET Expression Cut-offs in HCC Cohort
Supplementary Figure 3A from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Exploratory Analysis of Different MET Expression Cut-offs in HCC Cohort
Sl Figure 1 from Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Authors: Li Qiao , Guan Xiuwen , Chen Shanshan , Yi Zongbi , Lan Bo , Xing Puyuan , Fan Ying , Wang Jiayu , Luo Yang , Yuan Peng , Cai Ruigang , Zhang Pin , Li Qing , Zhong Dafang , Zhang Yifan , Zou Jianjun , Zhu Xiaoyu , Ma Fei , Xu Binghe
Published: April 2023

Reported diarrheal events over time in patients of all the cohorts.
Table S2 from Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer
Authors: Bernemann Christof , Humberg Verena , Thielen Barbara , Steinestel Julie , Chen Xin , Duensing Stefan , Schrader Andres J. , Boegemann Martin
Published: April 2023

Delta Ct values of AR-FL, AR-V3, AR-V7 and AR-V9 in LuCaP xenografts (Ct ARs - Ct RPL37A)
Tables S1-9 from Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas
Authors: Jonsson Philip , Lin Andrew L. , Young Robert J. , DiStefano Natalie M. , Hyman David M. , Li Bob T. , Berger Michael F. , Zehir Ahmet , Ladanyi Marc , Solit David B. , Arnold Angela G. , Stadler Zsofia K. , Mandelker Diana , Goldberg Michael E. , Chmielecki Juliann , Pourmaleki Maryam , Ogilvie Shahiba Q. , Chavan Shweta S. , McKeown Andrew T. , Manne Malbora , Hyde Allison , Beal Kathryn , Yang T. Jonathan , Nolan Craig P. , Pentsova Elena , Omuro Antonio , Gavrilovic Igor T. , Kaley Thomas J. , Diamond Eli L. , Stone Jacqueline B. , Grommes Christian , Boire Adrienne , Daras Mariza , Piotrowski Anna F. , Miller Alexandra M. , Gutin Philip H. , Chan Timothy A. , Tabar Viviane S. , Brennan Cameron W. , Rosenblum Marc , DeAngelis Lisa M. , Mellinghoff Ingo K. , Taylor Barry S.
Published: April 2023

Table S1: Patient-level clinical annotation. Table S2: Sample-level clinical annotation. Table S3: Patient-level treatment lines. Table S4: Gene panels for targeted sequencing. Table S5: Somatic mutations. Table S6: Gene-level copy number alterations. Table S7: Hotspot mutations in 3,130 sequenced glioma patients. Table S8: Pathogenic and likely pathogenic germline variants identified. Table S9: Pathways and gene content for cohort-wide pathway-level analyses.
Figure S3 from Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Authors: Peng Weiyi , Williams Leila J. , Xu Chunyu , Melendez Brenda , McKenzie Jodi A. , Chen Yuan , Jackson Heather L. , Voo Kui S. , Mbofung Rina M. , Leahey Sara Elizabeth , Wang Jian , Lizee Gregory , Tawbi Hussein A. , Davies Michael A. , Hoos Axel , Smothers James , Srinivasan Roopa , Paul Elaine M. , Yanamandra Niranjan , Hwu Patrick
Published: April 2023

In vivo effect of PI3K inhibition in combination with anti-OX40 treatment on T cell proliferation
Supplementary Table S4 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
Authors: Lazzari Luca , Corti Giorgio , Picco Gabriele , Isella Claudio , Montone Monica , Arcella Pamela , Durinikova Erika , Zanella Eugenia R. , Novara Luca , Barbosa Fabiane , Cassingena Andrea , Cancelliere Carlotta , Medico Enzo , Sartore-Bianchi Andrea , Siena Salvatore , Garnett Mathew J. , Bertotti Andrea , Trusolino Livio , Di Nicolantonio Federica , Linnebacher Michael , Bardelli Alberto , Arena Sabrina
Published: April 2023

Supplementary Table S4
Figure S1 from A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Authors: Song Yuqin , Wu Jianqiu , Chen Xinchuan , Lin Tongyu , Cao Junning , Liu Yanyan , Zhao Yaozhong , Jin Jie , Huang Haiwen , Hu Jianda , Luo Jun , Zhang Liling , Xue Hongwei , Zhang Qingyuan , Wang Weiwei , Chen Chunxia , Feng Jifeng , Zhu Jun
Published: April 2023

Efficacy outcome according to investigator's assessment
Supplementary Table S1 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy
Authors: Klanova Magdalena , Oestergaard Mikkel Z. , Trněný Marek , Hiddemann Wolfgang , Marcus Robert , Sehn Laurie H. , Vitolo Umberto , Bazeos Alexandra , Goede Valentin , Zeuner Harald , Knapp Andrea , Sahin Deniz , Spielewoy Nathalie , Bolen Christopher R. , Cardona Andres , Klein Christian , Venstrom Jeffrey M. , Nielsen Tina , Fingerle-Rowson Günter
Published: April 2023

Baseline patient and disease characteristics in FL and DLBCL patients with NKCCs available (analysis population) and in the GALLIUM and GOYA ITT populations.
Supplementary Figure 4 from Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Authors: Guillén Díaz-Maroto Natalia , Sanz-Pamplona Rebeca , Berdiel-Acer Mireia , Cimas Francisco J. , García Elena , Gonçalves-Ribeiro Samuel , Albert Nerea , Garcia-Vicién Gemma , Capella Gabriel , Moreno Victor , Salazar Ramon , Villanueva Alberto , Molleví David G.
Published: April 2023

Supplementary Figure 4
Supplementary Figure 3 from Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Authors: Guillén Díaz-Maroto Natalia , Sanz-Pamplona Rebeca , Berdiel-Acer Mireia , Cimas Francisco J. , García Elena , Gonçalves-Ribeiro Samuel , Albert Nerea , Garcia-Vicién Gemma , Capella Gabriel , Moreno Victor , Salazar Ramon , Villanueva Alberto , Molleví David G.
Published: April 2023

Supplementary Figure 3
Figure S3 from Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma
Authors: Nguyen Rosa , Moustaki Ardiana , Norrie Jacqueline L. , Brown Shantel , Akers Walter J. , Shirinifard Abbas , Dyer Michael A.
Published: April 2023

Supplementary Figure S3. NK cell ligands in SJNBL46_X passaged in NOD scid Il2rÎ³â^'/â^' (NSG) and nude mice. A, SJNBL46_X grew in NSG mice and was subsequently analyzed for the expression of NK cell ligands by flow cytometry and reinjected into nude mice. Forming tumors in nude mice underwent the same analysis. Histograms are shown for each ligand (red: NSG mouse, blue: nude mouse, black: isotype). B, The opposite experiment was performed, in which PDX was harvested from nude mice and reinjected into NSG mice. Histograms depict NK cell ligand expression in these tumors (red: nude mouse, blue: NSG mouse, black: isotype). The analysis showed that there were NK cell ligands that did not change expression when tumors from NSG mice were passaged through nude mice (e.g., ULBP2, DR4, CD112, MICA, and MICB) or vice versa (e.g., DR4, DR5, CD112, ULBP3, MICA, and MICB). There were other ligands that were downregulated. However, downregulation was noted in both sub-sets of experiments (e.g., NTB-A and CD155), suggesting that this was not due to host-related immune editing.
Supplementary Figure S6 from Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity
Authors: Current Kyle , Meyer Catherine , Magyar Clara E. , Mona Christine E. , Almajano Joel , Slavik Roger , Stuparu Andreea D. , Cheng Chloe , Dawson David W. , Radu Caius G. , Czernin Johannes , Lueckerath Katharina
Published: April 2023

PSMA expression in tumors with different fractions of PSMA-positive cells and growth of untreated tumors in study 4.
Figure S4 from Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Authors: Prabhu Varun V. , Madhukar Neel S. , Gilvary Coryandar , Kline C. Leah B. , Oster Sophie , El-Deiry Wafik S. , Elemento Olivier , Doherty Faye , VanEngelenburg Alexander , Durrant Jessica , Tarapore Rohinton S. , Deacon Sean , Charter Neil , Jung Jinkyu , Park Deric M. , Gilbert Mark R. , Rusert Jessica , Wechsler-Reya Robert , Arrillaga-Romany Isabel , Batchelor Tracy T. , Wen Patrick Y. , Oster Wolfgang , Allen Joshua E.
Published: April 2023

Figure S4
Supplementary Figure S1 from Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity
Authors: Current Kyle , Meyer Catherine , Magyar Clara E. , Mona Christine E. , Almajano Joel , Slavik Roger , Stuparu Andreea D. , Cheng Chloe , Dawson David W. , Radu Caius G. , Czernin Johannes , Lueckerath Katharina
Published: April 2023

Characteristics of the RM1 mouse model
Figure S3 from Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Authors: Prabhu Varun V. , Madhukar Neel S. , Gilvary Coryandar , Kline C. Leah B. , Oster Sophie , El-Deiry Wafik S. , Elemento Olivier , Doherty Faye , VanEngelenburg Alexander , Durrant Jessica , Tarapore Rohinton S. , Deacon Sean , Charter Neil , Jung Jinkyu , Park Deric M. , Gilbert Mark R. , Rusert Jessica , Wechsler-Reya Robert , Arrillaga-Romany Isabel , Batchelor Tracy T. , Wen Patrick Y. , Oster Wolfgang , Allen Joshua E.
Published: April 2023

Figure S3
Supplementary Data from T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells
Authors: Lapteva Natalia , Gilbert Margaret , Diaconu Iulia , Rollins Lisa A. , Al-Sabbagh Mina , Naik Swati , Krance Robert A. , Tripic Tamara , Hiregange Manasa , Raghavan Darshana , Dakhova Olga , Rouce Rayne H. , Liu Hao , Omer Bilal , Savoldo Barbara , Dotti Gianpietro , Cruz Conrad Russel , Sharpe Keli , Gates Melissa , Orozco Aaron , Durett April , Pacheco Elizabeth , Gee Adrian P. , Ramos Carlos A. , Heslop Helen E. , Brenner Malcolm K. , Rooney Cliona M.
Published: April 2023

Supplementary Figures
Supplementary Figure 1 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Authors: Lee Oukseub , Sullivan Megan E. , Xu Yanfei , Rogers Chiara , Muzzio Miguel , Helenowski Irene , Shidfar Ali , Zeng Zexian , Singhal Hari , Jovanovic Borko , Hansen Nora , Bethke Kevin P. , Gann Peter H. , Gradishar William , Kim J. Julie , Clare Susan E. , Khan Seema A.
Published: April 2023

Supplemental Figure 1. Validation of RNA seq results of responders by Nanostring nCounter gene expression assay.
Authorship Change forms from Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-κB Signaling
Authors: Ji Jianxiong , Xu Ran , Ding Kaikai , Bao Guoqing , Zhang Xin , Huang Bin , Wang Xinyu , Martinez Aurora , Wang Xiuying , Li Gang , Miletic Hrvoje , Thorsen Frits , Bjerkvig Rolf , Xiang Lei , Han Bo , Chen Anjing , Li Xingang , Wang Jian
Published: April 2023

Authorship Change forms
Figure S2 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Authors: Yan Zi-Xun , Li Li , Wang Wen , OuYang Bin-Shen , Cheng Shu , Wang Li , Wu Wen , Xu Peng-Peng , Muftuoglu Muharrem , Hao Ming , Yang Su , Zhang Mu-Chen , Zheng Zhong , Li James , Zhao Wei-Li
Published: April 2023

Supplementary Figure S2. Kinetics of peripheral blood CAR-T cells and serum biomarkers. (A) Bar plots showing the comparison of the peak value (mean {plus minus} SD) and the peak day (median {plus minus} IQR) of CAR T cells in DL1 (purple), DL2 (blue) and DL3 (red). (B) CAR-T cell count (mean {plus minus} SD) change over time from peripheral blood in the CR (green) and PR group (blue). (C) The concentration of serum biomarkers (mean {plus minus} SD) change over time in DL1 (purple), DL2 (blue) and DL3 (red). Student's t-test, one-way ANOVA, Wilcoxon signed-rank test or Friedman test was used, as appropriate. SD: Standard Deviation, IQR: interquartile range.
Supplementary Table 2 from Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types
Authors: Chen William S. , Alshalalfa Mohammed , Zhao Shuang G. , Liu Yang , Mahal Brandon A. , Quigley David A. , Wei Ting , Davicioni Elai , Rebbeck Timothy R. , Kantoff Philip W. , Maher Christopher A. , Knudsen Karen E. , Small Eric J. , Nguyen Paul L. , Feng Felix Y.
Published: April 2023

Pathway enrichment analysis for genes in RBS
Figure S2 from A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases
Authors: El Bouchtaoui Morad , Do Cruzeiro Marcio , Leboeuf Christophe , Loisel-Ferreira Irmine , Fedronie Carèle , Ferreira Chrystophe , Ait El Far Rachida , Ziol Marianne , Espié Marc , Falgarone Géraldine , Cassinat Bruno , Kiladjian Jean-Jacques , Feugeas Jean-Paul , Janin Anne , Bousquet Guilhem
Published: April 2023

Supplementary Figure S2
Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Authors: Roeker Lindsey E. , Fox Christopher P. , Eyre Toby A. , Brander Danielle M. , Allan John N. , Schuster Stephen J. , Nabhan Chadi , Hill Brian T. , Shah Nirav N. , Lansigan Frederick , Yazdy Maryam , Cheson Bruce D. , Lamanna Nicole , Singavi Arun K. , Coombs Catherine C. , Barr Paul M. , Skarbnik Alan P. , Shadman Mazyar , Ujjani Chaitra S. , Tuncer Hande H. , Winter Allison M. , Rhodes Joanna , Dorsey Colleen , Morse Hannah , Kabel Charlene , Pagel John M. , Williams Annalynn M. , Jacobs Ryan , Goy Andre , Muralikrishnan Sivraj , Pearson Laurie , Sitlinger Andrea , Bailey Neil , Schuh Anna , Kirkwood Amy A. , Mato Anthony R.
Published: April 2023

Supplemental Table 1 and Supplemental Figure Legends